Monthly Archives: January 2022
Boris Johnson and ‘Partygate’: he who lives by the Brexit sword, dies by the Brexit sword
This article is republished from The Conversation under a Creative Commons license. Read the original article here. Boris Johnson’s time as the United Kingdom’s prime minister is under immediate threat. Johnson, who likes a classical analogy, will know that civil servant Sue Gray’s imminent report into the “Partygate” scandal is the bureaucratic equivalent of the…
Schools can expect a year of disruption. Here are 7 ways they can help support the well-being of students and staff
This article is republished from The Conversation under a Creative Commons license. Read the original article here. There’s just over a week to go before term one starts across the country – except in Queensland which has pushed back the start of the school year. We are yet to see states and territory plans for…
Coalition slumps in first poll of 2022 as voters lose confidence in Morrison’s handling of pandemic
This article is republished from The Conversation under a Creative Commons license. Read the original article here. In the first national poll of the new year, a Resolve survey for the Nine newspapers, Labor had 35% of the primary vote (up three percentage points since November), the Coalition 34% (down five), the Greens 11% (steady),…
Tonga recovery: one day at a time
Source link – ANZ Bluenotes Tonga recovery: one day at a time Source link – ANZ Bluenotes
Australia approves two new medicines in the fight against COVID. How can you get them and are they effective against Omicron?
This article is republished from The Conversation under a Creative Commons license. Read the original article here. On Thursday, health minister Greg Hunt announced Australia’s drug regulator had provisionally approved two new medicines for the treatment of COVID. These are Lagevrio, made by American pharmaceutical company Merck Sharpe & Dohme, and Paxlovid, by Pfizer. With…
Cryptocurrency: don’t look up
Source link – ANZ Bluenotes Tragically this has cost space jockey and Tesla founder Elon Musk about $US25 billion but it is hardly unusual in the short history of cryptocurrencies. For those with the risk appetite, the attraction of cryptos is precisely that they are untethered to the real world and hence inherently volatile. “Why…
CORBEVAX, a new patent-free COVID-19 vaccine, could be a pandemic game changer globally
This article is republished from The Conversation under a Creative Commons license. Read the original article here. The world now has a new COVID-19 vaccine in its arsenal, and at a fraction of the cost per dose. Two years into the COVID-19 pandemic, the world has seen over 314 million infections and over 5.5 million…
Why Novak Djokovic lost his fight to stay in Australia – and why it sets a concerning precedent
This article is republished from The Conversation under a Creative Commons license. Read the original article here. Many sports stars are, rightly or wrongly, held up as role models. In the case of Novak Djokovic, we have a set of powerful factors at play. On one side is a tennis superstar who is unvaccinated and…
IN CHARTS: commodities navigate supply risks
Source link – ANZ Bluenotes The rise in Omicron case numbers has stifled road traffic in many countries. Global commercial flight numbers are also slowing and US air travel tanked during the New Year holiday. Brent oil’s forward curve is steepening, reflecting supply tightness in the oil market. Backwardation widened to $US9 per…
‘Welcome to our world’: families of children with cancer say the pandemic has helped them feel seen, while putting them in peril
This article is republished from The Conversation under a Creative Commons license. Read the original article here. For billions of people across the world, life as we knew it stopped in 2020. Families and friends were separated. Masks mandated. Hand washing essential. Every trip outside became risky. As news of deaths, variants and long-term effects…